Life Sciences

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013
15 April 2026

Citryll Strengthens Intellectual Property Portfolio With Grant of European Composition of Matter Patent for CIT-013

Oss, Netherlands – 15 April 2026 – Citryll, a biotech company pioneering a transformative approach to treating immune-mediated inflammatory diseases by targeting...

Read more
Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis
2 April 2026

Vedanta Biosciences Announces the Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection Will Continue as Planned Following Protocol-Specified Interim Analysis

Vedanta Biosciences, a late clinical-stage biopharmaceutical company developing microbiome-based oral therapies for gastrointestinal diseases, today announced that the...

Read more
Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein
31 March 2026

Standing Ovation raises $34.2 million to scale up its breakthrough technology for producing dairy proteins through precision fermentation, offering a sovereign and sustainable response to the surge in global demand for protein

Paris, 31 March 2026 - Standing Ovation, a French precision fermentation pioneer producing next-
generation proteins, has announced a $34.2 million (€30 million) Series...

Read the press release
Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis
11 February 2026

Microbiotica Announces Impressive Results in its Phase 1b Trial of MB310 in Ulcerative Colitis

Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces positive...

Read more
Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors
29 January 2026

Enterome appoints leading hematologist and IFLI Executive Partner Mehrdad Mobasher, M.D., M.P.H., to its Board of Directors

Enterome SA, a clinical-stage company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies that induce a fast and potent expansion of...

Read more
ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate
21 January 2026

ErVimmune raises €17 million in Series A first closing to enter clinical development with lead cancer vaccine candidate

ErVimmune, a biotechnology company developing next-generation therapeutic vaccines targeting new families of ‘unconventional’ tumor antigens derived from human endogenous...

Read more
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis
20 January 2026

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in Advanced NSCLC Patients with Antibiotic-Induced Dysbiosis

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overcome ICI Resistance in...

Read more
Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases
10 December 2025

Vertero Establishes Scientific Advisory Board to Advance Innovation in Neurodegenerative Diseases

Vertero Therapeutics, a clinical-stage biotechnology company breaking barriers in neurodegenerative disease treatment, today announced the appointment of five globally...

Read more
MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival
8 December 2025

MaaT Pharma Presents Pivotal ARES Phase 3 Results for MaaT013 (Xervyteg®) in Acute GvHD at ASH 2025 Annual Congress and Announces 54% 1-Year Overall Survival

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated...

Read more